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Abstract
Background: Health Related Quality of Life (HRQoL) is an important outcome in times of Highly
Active Antiretroviral Treatment (HAART). We compared the HRQoL of HIV positive patients
receiving HAART with those awaiting treatment in public sector facilities in the Free State province
in South Africa.
Methods:  A stratified random sample of 371 patients receiving or awaiting HAART were
interviewed and the EuroQol-profile, EuroQol-index and Visual Analogue Scale (VAS) were
compared. Independent associations between these outcomes and HAART, socio-demographic,
clinical and health service variables were estimated using linear and ordinal logistic regression,
adjusted for intra-clinic clustering of outcomes.
Results: Patients receiving HAART reported better HRQoL for 3 of the 5 EuroQol-dimensions,
for the VAS score and for the EuroQol index in bivariable analysis. They had a higher mean
EuroQol index (0.11 difference, 95% confidence interval [CI] 0.04; 0.23), and were more likely to
have a higher index (odds ratio 1.9, 95% CI 1.1; 1.3), compared to those awaiting HAART, in
multivariate analysis. Higher mean VAS scores were reported for patients who were receiving
HAART (6.5 difference, 95% CI 1.3; 11.7), were employed (9.1, 95% CI 4.3; 13.7) or were female
(4.7, 95% CI 0.79; 8.5).
Conclusion: HAART was associated with improved HRQoL in patients enrolled in a public sector
treatment program in South Africa. Our finding that the EuroQol instrument was sensitive to
HAART supports its use in future evaluation of HIV/AIDS care in South Africa. Longitudinal studies
are needed to evaluate changes in individuals' HRQoL.
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Background
Globally an estimated 40.3 million people were living
with HIV/AIDS by the end of 2005, with two thirds of the
world's burden in sub-Saharan Africa [1]. In South Africa
alone, about 5.2 million people were HIV positive in 2005
of which 520,000 had AIDS [2]. HIV/AIDS is South
Africa's leading cause of death and was responsible for
38% of premature mortality by 2000 [3]. AIDS also
impairs Health Related Quality of Life (HRQoL), which is
an important measurable outcome of HIV treatment in
the era of Highly Active Antiretroviral Treatment
(HAART), complementing more objective outcomes such
as death [4-8]. HAART not only reduces opportunistic
infections and AIDS related mortality [9-12] but also
improves HRQoL, as demonstrated repeatedly, both in
developed nations and also recently in a small South Afri-
can cohort treated with HAART [13-17]. The latter study
demonstrated progressive improvement in HRQoL during
a 12 month follow-up period in a pilot project run in a
resource poor setting in the Western Cape, one of South
Africa's provinces. While these findings are promising, the
effectiveness of large scale HAART roll-out in South Africa
is not yet known.
HRQoL can be measured with a variety of multidimen-
sional generic and disease specific instruments, some of
which have been specifically developed for people living
with AIDS [8,18-21]. One commonly used generic meas-
ure is the EuroQol questionnaire, developed by the Euro-
Qol Group. This standardized, widely validated and tested
instrument provides a simple descriptive 5-dimensional
profile (EQ-5D), a utility-based index of health status,
and the EQ-Visual Analogue Scale (EQ-VAS) [22-29].
The EQ-5D descriptive system defines health in terms of
five domains: mobility, self care, usual activities, pain or
discomfort and anxiety or depression. Each domain has
three levels: no problems, some/moderate problems and
extreme problems. This information can be presented as
an EQ-5D profile with results reported separately for each
domain. Also, the 243 possible combinations of health
states can be converted into a single weighted health
index, the EQ index, by applying weights derived from
studies among general population samples. The most
widely used weights are the York tariffs, generated from a
survey of 3395 adults in the United Kingdom [23,24]. In
that study respondents were asked to select a length of
time with perfect health that they regarded as equivalent
to 10 years with a defined state of poor health [23].
Extrapolations for the 200 other possible health states
were modeled mathematically [24]. Values of the EQ
index can range from – 0.594 to 1, the negative values
referring to a state of health regarded as worse than death.
The EQ-VAS records the respondent's self-rated health sta-
tus on a standard 20 cm long graduated visual analogue
interval scale (from 0, the worst imaginable state of health
to 100, the best imaginable state of health). Respondents
rate their health state by drawing a line from the box
marked "Your health state today" to the appropriate point
on the EQ-VAS. A three-digit number between 000 and
100 is read off the scale from the exact point where the
line crosses the scale. The EQ-VAS can be used together
with the descriptive system to gain a composite picture of
the respondent's health status or to track changes over
time. It reflects the respondent's own assessment of his
health status, in contrast to the index, which can be
regarded as a societal value of the respondent's health sta-
tus [30].
A review of seven generic quality-of-life instruments
found that the reliability and validity of the EuroQol com-
pared well with other instruments although it was rela-
tively insensitive to mildly impaired health states [31].
Although not specifically designed for HIV/AIDS, this
measure has also been validated, tested for reliability and
successfully applied in populations living with AIDS
[6,32-35]. Delate and Coons provide evidence for the con-
struct validity of the MOS-HIV and EQ-5D in HIV positive
clients [32]. They found statistically significant correla-
tions between the EQ-5D index and HIV -1 viral loads,
between EQ-5D VAS scores and CD4 cell counts, between
EQ-5D VAS scores, MOS-HIV Physical Health scores and
MOS-HIV Mental Health Scores, but not between EQ-5D
index and CD4 cell counts. They also found moderate to
strong correlations between MOS-HIV subscales and the
EQ-5D index, between MOS-HIV subscales and the VAS-
score and between the MOS-HIV summary score and both
the as well EQ-5D index and the EQ-VAS in another clin-
ical trial [33]. A South African study found that people liv-
ing with AIDS reported a significantly lower quality of life,
as measured with the EuroQol, than people without AIDS
did [6]. The instrument was demonstrated to be a brief
and prognostically useful predictor of mortality, hospital-
ization and emergency department utilization in HIV-
infected adults in United States based adult HIV clinic
[35]. In a recent comparative review of HRQoL measures
for use in HIV/AIDS clinical trials, EQ-5D was one of the
three generic outcome measures considered worthy for
use in trials alongside a disease-targeted measure.
Although not ideal for relatively healthy populations
because of the ceiling effects, for trials with more
advanced disease, the brevity of the EQ-5D was consid-
ered an advantage [36].
During 2004 HAART was introduced in South Africa's
public sector HIV prevention and care program [37]. The
Free State province, one of South Africa's nine provinces
with high HIV burden, adapted this program to its specific
needs, initially introducing a cluster of 1 hospital-based
treatment site and 3 primary care assessment clinics in 4BMC Public Health 2007, 7:244 http://www.biomedcentral.com/1471-2458/7/244
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districts and combined sites in the fifth, sparsely popu-
lated district [38]. Antiretroviral treatment services were
introduced in a stepwise fashion across health districts
over the course of 8 months. Patients testing positive for
HIV are referred from any primary health care facility to a
nurse clinician at an assessment clinic for CD4 testing and
clinical evaluation. Those with a CD4 count below 200
cells/µl or WHO stage 4 are referred to the designated
treatment site at a hospital for doctor's confirmation of
clinical eligibility for HAART. Treatment is deferred for 2
months in patients with active tuberculosis. Patients certi-
fied as ready for treatment by the doctor, undergo a
month long treatment readiness program before drug ini-
tiation. Patients are monitored on a monthly basis at the
clinics, with 3 monthly review by the hospital doctor.
This study is part of a large ongoing multidisciplinary
patient survey on patients' experiences of HAART, con-
ducted by the Centre for Health Systems Research and
Development of the University of the Free State. The pur-
pose of this sub-study was to describe and compare the
HRQoL of patients already receiving HAART with those
awaiting HAART, for all 5 health districts. We also aimed
to investigate relationships between socio-demographic,
clinical, support system and health care factors and
HRQoL. The study is the first of its kind to measure
HRQoL in a wide-scale public sector roll-out of antiretro-
viral treatment in South Africa.
Methods
Population and sampling
This was a cross-sectional interview survey. The study pop-
ulation was all 1173 patients 18 years and older enrolled
in the public sector HAART program in the Free State,
sampled 2 months after treatment initiation of the first
patients in each district. These included both patients
already receiving public sector HAART and those not yet
receiving HAART, but certified by a designated doctor as
qualifying for treatment on the basis of CD4 counts below
200 cells/µl and/or WHO stage 4 AIDS. During this wait-
ing period patients were required to attend the treatment
readiness program. The study population excluded
patients during the first 2 months of TB treatment and
patients with other severe opportunistic infections which
necessitated other treatment before HAART could be initi-
ated.
A stratified random sample of patients was selected from
all five districts, and from all 16 clinics providing HAART
by means of anonymous patient lists obtained from all
facilities. For each district 80 patients were randomly sam-
pled, proportional to the numbers of patients per clinic
and per treatment group (on HAART, awaiting HAART).
In one district with fewer than 80 patients, a census of all
treatment and non-treatment cases was conducted. We
aimed for a sample size of 400, which provided 86%
power, at the 5% significance level, to detect a 15% differ-
ence in proportions between groups (65% vs. 80%), with
double as many patients on treatment as those awaiting
treatment.
Measurements
Respondents were interviewed face-to-face by trained
interviewers using 2 standard paper based questionnaires
– 1 for treatment and 1 for non-treatment patients, the
former with additional treatment specific questions.
Questions on socio-economic and demographic charac-
teristics were taken from the 1996 South African census.
The EQ-5D-questionnaire was used to gather information
on HRQoL. Subjects were also asked about socio-demo-
graphic characteristics, whether they had previously
received antiretroviral treatment outside of the public sec-
tor program, recent hospitalization, smoking, alcohol and
drug use and whether they had a physical or emotional
caregiver or a treatment supporter. The questionnaires
were translated into Afrikaans, English, Sotho, isiXhosa
and Zulu, but because of patient demographics, only the
Afrikaans, English and Sotho versions were administered.
For the EQ-5D, best available translations into Afrikaans,
isiXhosa, Zulu and Sotho, which had previously been
completed by a number of Southern African researchers
according to standards set by the EuroQol Group, were
used [39-41]. Where possible, interviews were held at
assessment clinics with home visits being conducted in
cases where this was not feasible. Treatment starting dates
were obtained by interviews and from patient records.
The questionnaire was piloted by two researchers among
three Department of Health staff members receiving
HAART in the private sector. Data quality control took
place at three levels: in-field editing, site visit editing and
data editing. Test-retest reliability was not assessed
because it was not feasible for patients to return for a later
interview within the recommended one to two weeks,
solely for this purpose [42]. It was also plausible that their
health states could change rapidly.
Written consent for the interviews and for access to the
clinical records was obtained from all participating
patients. The study was approved by the Ethics Committee
of the Faculty of Humanities of the University of the Free
State and was registered with the EuroQol group. Study
results were treated confidentially.
Analysis
All data analysis was performed with the statistical soft-
ware package Stata Version 8.0. The researchers calculated
the EQ index values for each of the respondents, weighted
by the York tariffs [23,24]. Treatment duration wasBMC Public Health 2007, 7:244 http://www.biomedcentral.com/1471-2458/7/244
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defined as the time from start of treatment to date of inter-
view. Treatment duration was categorized with cut points
at 0/1, 29/30, 59/60 and 89/90 days.
Descriptive statistics were used to describe the health sta-
tus and other socio-demographic and behavioral charac-
teristics of the subjects. Simple logistic, ordinal logistic
and linear regressions as well non-parametric tests were
used to identify potential predictors of the 5 EQ-domains,
the VAS and the EQ index score and potential confound-
ers of belonging to the HAART group vs. the non-HAART
group. Simple ordinal logistic regression was used to com-
pare EuroQol dimensions between patients on HAART
and those awaiting HAART. Regression analyses were
adjusted for intra-clinic clustering of outcomes using
Stata's Huber-White robust sandwich estimator. Cuzick's
non-parametric test for trend was used to measure trends
in the index and the VAS scores across ordered treatment
duration categories [43]. Spearman's rank correlation test
was used to test for correlation between non-normally dis-
tributed numerical variables. The inter-item correlation of
the 5 component dimensions of the EQ-5D index was
estimated using Cronbach's alpha.
EQ index scores were not normally distributed and so
were analyzed as follows. First, we divided the index into
three ordered index categories for analysis with multiple
ordinal logistic regression. All EQ index values of 1 were
included in the highest category to reduce non-differential
misclassification. Second, we performed bootstrapped
multiple linear regression using cluster (clinic) sampling,
with 1000 replications, and obtained bias-corrected accel-
erated percentile confidence intervals for regression coef-
ficients [44]. For the VAS score, regression diagnostics
showed that linear regression was appropriate. The
explanatory variables initially used in the models with
VAS and EQ index as outcomes were total personal
income, sex, employment status, previous antiretroviral
treatment, recent hospitalization, having a physical or
emotional caregiver or a treatment buddy, education,
rooms in house, age, treatment site and treatment dura-
tion or treatment group. Explanatory variables were
removed from each model if their adjusted p-value was
more than 0.05 and if removing them did not change the
odds ratio or beta-coefficient for treatment by more than
10%. Analyses accounted for the stratified sampling by
including district as a covariate, and for intra-clinic corre-
lation of outcomes by robust error adjustment.
Results
Patients' demographic, socioeconomic and health 
characteristics
A total of 371 patients were interviewed (268 on treat-
ment and 103 awaiting treatment). Median treatment
duration, for those on treatment with known treatment
duration (220 patients), was 70 (IQR 38.5–90) days.
Interviewees were young (75% aged <43 years), with
nearly twice as many women as men (65% vs. 35%),
largely unemployed (85%) and dependent on social
grants (49%). Three quarters of respondents (74%) lived
in houses with 4 or less rooms and 67% had completed 10
or less of the 12 grades of primary and secondary school
(Table 1). The HAART group differed significantly from
the non-HAART group in terms of socio-economic status
as indicated by income (p = 0.005), housing size (p =
0.017) and employment status (p = 0.008), but not by
educational level or access to grants. No respondent
reported consuming cannabis, while a similarly small per-
centage of both groups reported alcohol consumption or
smoking. Predictably, the HAART group reported having a
treatment buddy significantly more often than the non-
treatment group (p = 0.007). Patients already on antiret-
roviral treatment when accessing the program received
preferential access so as to limit treatment interruptions.
This is reflected in the higher proportion of previously
treated patients in the HAART group (p = 0.006).
Socio-demographic and patient support variables associ-
ated with HRQoL are presented in Table 2. Males were
more likely than females to report problems in some
domains. Unemployed patients were more likely than
employed patients to report problems in some domains,
and had significantly worse EQ index and VAS values.
Patients with a physical caregiver reported a lower quality
of life for all EuroQol measures.
Cronbach's alpha for the EQ index was 0.85, indicating a
high degree of correlation between the five dimensions.
The EQ index correlated well with VAS scores (Spearman's
ρ = 0.48, Pearson's R2 = 0.29).
Influence of HAART on Health Related Quality of Life
The EQ-5D results showed that patients awaiting HAART
commonly reported problems, with 57% reporting that
pain or discomfort caused problems, 42% reporting that
depression or anxiety caused problems, 29% reporting
problems with mobility, and with an EQ index of 0.69
and a VAS score of 62. Respondents on HAART were sig-
nificantly less likely than those awaiting treatment to
report a higher problem score for 3 of the 5 EQ domains.
Their median EQ index (0.87 vs. 0.80, p = 0.04) and VAS
scores (70 vs. 60, p = 0.04) were higher than for those
awaiting treatment (Table 3). Secondary analysis of the
data with exclusion of respondents who, at enrollment in
the public sector program, had previously received antiret-
roviral treatment produced similar results. There was a
trend of higher index scores for consecutive treatmentBMC Public Health 2007, 7:244 http://www.biomedcentral.com/1471-2458/7/244
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duration groups (p = 0.03), but this was not the case for
the VAS score (p = 0.29).
Table 4 shows the influence of HAART on the EQ index,
adjusted for employment status and district and for intra-
clinic clustering of outcome. Patients on HAART were
nearly twice as likely to have a higher index as those await-
ing HAART. Employed respondents were more likely to
have a higher HRQoL than unemployed respondents, but
this did not reach statistical significance. Using linear
regression with bootstrapping, patients on HAART had on
average a 0.11 higher index than those not on HAART
while patients with a physical caregiver had a lower index
score than those who did not have a physical caregiver.
Similarly, being on HAART was associated with a 6.5
higher VAS score, compared to those not on HAART, inde-
pendent of the positive effects of employment and being
female on self-reported HRQol (Table 5).
Discussion
This study shows independent associations between
HAART and measures of HRQoL, despite the relatively
short treatment duration. This was true for both the VAS
score and the EQ index. This supports a cohort study of
HAART patients in Khayelitsha township in the Western
Cape province [34] that found improved EQ-5D after 12
months of treatment. The effect of HAART on VAS esti-
mated in the present study (6.5 points, Table 4) was
smaller than reported in the Khayelitsha study (14.4
points increase after 12 months). These two studies results
are however, not directly comparable because in our study
the duration of treatment was shorter, our design was
cross-sectional rather than longitudinal, and we adjusted
for gender and employment status whereas that study did
not [34].
These findings are also in keeping with comparable Euro-
pean studies. Tramarin et al. compared the HRQoL of a
historical cohort of Italian AIDS patients not on HAART,
with a matched cohort on HAART, with both groups fol-
lowed up for 6 months [16]. The HAART cohort had far
fewer severe and total disability days than the 1994
cohort. Furthermore, the HAART cohort had significantly
higher scores at the end of the 6-month follow-up in two
of the Nottingham Health Profile dimensions (energy and
emotional reactions), while in the non-HAART group no
statistically significant changes were observed over 6
months. Similarly, Carrieri et al. demonstrated that a year
of HAART leads to significant improvements in most
dimensions of the Medical Outcome 36 item Short Form
Survey [17]. In another European cohort study, the socio-
demographic, biological and clinical predictors of HRQoL
of 809 HIV-infected patients were assessed with multivar-
iate models at baseline and at 6 months follow-up, using
the Medical Outcome Survey-HIV [45]. Symptoms, previ-
ous hospitalization, satisfaction with information and
education were associated with physical and mental
health. Not taking antiretroviral therapy at the baseline
Table 1: Patients' demographic, socioeconomic and health characteristics
All respondents 
(N = 371)
Receiving HAART 
(N = 268)
Awaiting HAART 
(N = 103)
P-value*
Median (IQR) Median (IQR) Median (IQR)
Age 37 (31–43) 37 (32–44) 36 (31–41) 0.17
Personal income (ZAR per month)** 740 (0–740) 740 (0–780) 740 (0–740) 0.005
n (%) n (%) n (%)
Female 243 (65) 176 (66) 67 (65) 0.88
Education ≤ grade 10 249 (67) 180 (67) 69 (67) 0.98
Health insurance 11 (3) 8 (3) 3 (3) 0.98
Employed 54 (15) 45 (17) 9 (9) 0.008
Receiving welfare grant 182 (49) 132 (49) 51 (50) 0.96
≤ 4 rooms in home 273 (74) 186 (69) 87 (84) 0.017
Smoked past 30 days 41 (11) 26 (10) 15 (15) 0.29
Drank alcohol past 30 days** 18 (5) 11 (4) 7 (7) 0.33
Has physical caregiver 131 (35) 90 (34) 41 (40) 0.46
Has emotional caregiver 178 (48) 123 (46) 55 (53) 0.21
Has treatment buddy 166 (45) 136 (51) 30 (29) 0.007
Previous antiretroviral treatment 25 (7) 24 (9) 1 (1) 0.006
Hospitalized since entering HAART 
program
37 (10) 25 (9) 12 (12) 0.62
*Simple logistic regression adjusted for intraclinic clustering of outcomes
** 1 missing valueB
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Table 2: Health-related quality of life by selected socio-demographic and patient support variables
Male 
(N = 128)
Female 
(N = 243)
P Unemployed 
(N = 317)
Employed 
(N = 54)
P No Physical 
caregiver 
(N = 239)
Physical caregiver 
(N = 131)
P
n (%) n (%) n (%) n (%) n (%) n (%)
Mobility
No problems 95 (74) 196 (81) 0.031* 243 (77) 48 (89) 0.15* 194 (81) 97 (74) 0.031*
Some problems 28 (22) 45 (19) 68 (21) 5 (9) 43 (18) 29 (22)
Severe problems 5 (4) 2 (1) 6 (2) 1 (2) 2 (1) 5 (4)
Self care
No problems 112 (88) 225 (93) 0.23* 286 (90) 51 (94) 0.32* 224 (94) 112 (86) 0.001*
Some problems 10 (8) 14 (6) 22 (7) 2 (4) 11 (5) 13 (10)
Severe problems 6 (5) 4 (2) 9 (3) 1 (2) 4 (2) 6 (5)
Usual activities**
No problems 92 (72) 197 (81) 0.034* 242 (77) 47 (87) 0.040* 195 (82) 94 (72) 0.06*
Some problems 24 (19) 37 (15) 55 (17) 6 (11) 35 (15) 25 (19)
Severe problems 12 (9) 8 (3) 19 (6) 1 (2) 8 (3) 12 (9)
Pain/discomfort
None 71 (55) 136 (56) 0.84* 167 (53) 40 (74) 0.009* 143 (60) 64 (49) 0.012*
Some 47 (37) 93 (38) 126 (40) 14 (26) 89 (37) 50 (38)
Severe 10 (8) 14 (6) 24 (8) 0 (0) 7 (3) 17 (13)
Depression/anxiety
None 80 (63) 168 (69) 0.28* 210 (66) 38 (70) 0.56* 170 (71) 78 (60) 0.006*
Some 34 (27) 60 (25) 82 (26) 12 (22) 54 (23) 39 (30)
Severe 14 (11) 15 (6) 25 (8) 4 (7) 15 (6) 14 (11)
Median (IQR) Median (IQR) Median (IQR) Median (IQR) Median (IQR) Median (IQR)
Index Score 0.85 (0.69–1) 0.85 (0.73–1) 0.27& 0.85 (0.69–1) 1 (0.73–1) 0.027& 1 (0.73–1) 0.80 (0.62–1) 0.001&
VAS score 60 (50–80) 70 (50–80) 0.08& 60 (50–80) 70 (60–83) 0.003& 70 (50–80) 60 (50–73) 0.004&
* Ordinal logistic regression adjusted for intraclinic clustering of outcomes
** Information missing for 1 respondent
&Wilcoxon rank sum test
Percentages for some dimensions do not add up to 100% because of rounding errorsBMC Public Health 2007, 7:244 http://www.biomedcentral.com/1471-2458/7/244
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was significantly associated with poor physical health in
the bivariable analysis, but not after adjustment for other
variables in the model.
HRQoL results are not a function of physical health state
alone. Socio-economic and demographic factors, such as
income, employment status, education and gender may
influence self-perceived HRQoL, independent of health
status [26,28,29]. In our study unemployed people had a
lower VAS and somewhat lower index score than
employed people. This could be because that sicker peo-
ple are more likely to leave work, rather than joblessness
Table 4: Predictors of EQ index*
Explanatory variable Odds ratio** 95% CI*** P-value***
Ordinal logistic regression model
On HAART vs. awaiting HAART 1.9 1.1–3.2 0.019
Employed vs. unemployed 1.7 0.91–3.2 0.10
Explanatory variable Coefficient**** 95% CI***
Linear regression with bootstrapping
On HAART vs. awaiting HAART 0.11 0.04; 0.23 -
Physical caregiver vs. none -0.12 -0.21; -0.04 -
* Variables initially entered in model: total personal income, sex, employment status, previous antiretroviral treatment, recent hospitalization, 
having a physical or emotional caregiver or a treatment buddy, education, rooms in house, age, treatment site and treatment duration or treatment 
group
** Odds ratio of having a higher index
*** Adjusted for district and for intra-clinic clustering of outcome
**** Difference in mean index values
Table 3: Health-related quality of life of patients on HAART vs. those awaiting HAART
All respondents (N = 371) Receiving HAART (N = 268) Awaiting HAART (N = 103) P-value
EQ-5 Dimensions n (%) n (%) n (%)
Mobility
No problems 291 (78) 218 (81) 73 (71) 0.026*
Some problems 73 (20) 48 (18) 25 (24)
Severe problems 7 (2) 2 (1) 5 (5)
Self care
No problems 337 (91) 252 (94) 85 (83) 0.001*
Some problems 24 (6) 13 (5) 11 (11)
Severe problems 10 (3) 3 (1) 7 (7)
Usual activities**
No problems 289 (78) 216 (81) 73 (71) 0.07*
Some problems 61 (16) 42 (16) 19 (18)
Severe problems 20 (5) 9 (3) 11 (11)
Pain/discomfort
None 207 (56) 162 (60) 45 (44) 0.022*
Some 140 (38) 92 (34) 48 (47)
Severe 24 (6) 14 (5) 10 (10)
Depression/anxiety
None 248 (67) 188 (70) 60 (58) 0.15*
Some 94 (25) 61 (23) 33 (32)
Severe 29 (8) 19 (7) 10 (10)
Index score
Median (IQR) 0.85 (0.69–1) 0.87 (0.73–1) 0.80 (0.66–1) 0.004$
Mean (SD) 0.77 (0.33) 0.80 (0.29) 0.69 (0.40)
VAS score
Median (IQR) 65 (50–80) 70 (50–80) 60 (50–70) 0.04$
Mean (SD) 65 (20) 66 (20) 62 (23)
* Ordinal logistic regression adjusted for intraclinic clustering of outcomes
** Information missing for 1 respondent
$ Wilcoxon rank sum test
Percentages for some dimensions do not add up to 100% because of rounding errorsBMC Public Health 2007, 7:244 http://www.biomedcentral.com/1471-2458/7/244
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itself affecting well-being, so longitudinal studies are
needed to distinguish the direction of this effect. Unlike in
other studies, income was not an independent predictor
of HRQoL [29]. This could be because the main source of
income of our population was in the form of disability
grants. Beneficial effects of income may have been offset
by higher levels of disability among grant recipients.
Women rated their health higher than men on the VAS,
which contrasts with a previous finding of poorer ratings
of women using the World Health Organization QoL HIV
questionnaire [20]. In our study, women may have less
advanced stages of disease when seeking health care. Pre-
liminary analysis of CD4 count results of patients enrolled
in the Free State HAART program suggest their pretreat-
ment CD4 counts are higher (L. Fairall, personal commu-
nication, February 2006). But HRQoL reflects a complex
interaction of many factors other than health status. In a
South African community based survey, the presence of a
disability, an income below US$140 per month, unem-
ployment and age in years were independent predictors of
the VAS score [29]. A large UK survey found variations in
health status measured with EuroQol, across social
classes, age, gender, education, housing tenure and mari-
tal status [26]. Employed people and better educated peo-
ple reported significantly less problems. Years of
education was found to be an independent predictor of
the EQ-VAS in patients with rheumatoid arthritis in the
United Kingdom and employed patients had significantly
higher EQ index and EQ-VAS scores than retired and
unemployed people [28].
Our study had several limitations. Most importantly, as it
was not a randomized trial it could be biased by unmeas-
ured confounders. The treatment duration, for many
respondents, was too short for the HAART effects to be
shown. Because of the cross-sectional nature of the study,
the inferences we can draw about causal relationships are
limited. We could not adjust treatment effects for impor-
tant clinical predictors, such as CD4 counts, viral loads
and disease stage, which are known to be associated with
HRQoL [17]. Waiting for HAART could also have
decreased HRQoL. However, the quality of life measures
were significantly different for patients receiving vs. those
awaiting HAART, for three of the five EQ-5D domains, for
the EQ index and for the VAS scale, with and without
adjustment for confounders, so these differences are
unlikely to be due to type 1 errors.
A general problem of generic quality of life measures is
that they are insensitive to illnesses that are not severe.
The valuations, or weightings, for the EQ index score were
derived from the UK population. It is notable that those
valuations depended on the age and the sex of respond-
ents: equivalent health states among those aged 18–59
had higher valuations then those aged over 60 and men
had higher valuations then women [23]. Valuations in a
South African population may differ because of different
socio-demographic characteristics and different cultural
attitudes towards health and disease [46]. The EQ index
may be better suited for economic evaluation studies than
for clinical studies [30] and the EuroQol instrument does
not capture all relevant dimensions of HRQoL such as
social relationships, sexuality and spirituality [20]. The
EQ-5D question on anxiety and depression does not dis-
tinguish between these two different constructs, which
may be problematic in this context. Nonetheless, its sim-
plicity, previous validation and use in South African pop-
ulations, including in people with HIV, and comparability
with other studies, made it appropriate for this study. As
part of our wider research project, we plan to assess partic-
ipating patients' changes in HRQoL on a 6-monthly basis
over a period of at least 3 years and to complement inter-
view data with clinical data to get a more detailed picture
of factors influencing HRQoL.
Conclusion
This cross-sectional study suggests that HAART is effective
in improving people's self-reported HRQoL. Further stud-
ies are needed to assess the influence of unmeasured con-
founders on the results and longer term effects. The
EuroQol instrument is a useful instrument to monitor
AIDS related patient outcomes, in addition to clinical
endpoints such as incidence of opportunistic infections
and death. It is easy to measure and takes into account
Table 5: Predictors of Visual Analogue Scale score*
Explanatory variable Coefficient* 95% CI* P-value**
On HAART vs. awaiting HAART 6.5 1.3–11.7 0.018
Employed vs. unemployed 9.1 4.3–13.7 0.001
Female vs. male 4.7 0.79–8.5 0.021
* Multiple linear regression model with the following variables initially entered in model: total personal income, sex, employment status, previous 
antiretroviral treatment, recent hospitalization, having a physical or emotional caregiver or a treatment buddy, education, rooms in house, age, 
treatment site and treatment duration or treatment group
** Adjusted for district and for intra-clinic clustering of outcomeBMC Public Health 2007, 7:244 http://www.biomedcentral.com/1471-2458/7/244
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patients' points of view. Our finding that the EQ-5D was
highly sensitive to HAART supports its use in future eval-
uation of HIV/AIDS care in South Africa.
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